Tactile Systems Technology ( (TCMD) ) has released its Q2 earnings. Here is a breakdown of the information Tactile Systems Technology presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tactile Systems Technology, Inc., operating as Tactile Medical, is a medical technology company specializing in developing and marketing at-home therapies for chronic conditions such as lymphedema, lipedema, and chronic venous insufficiency, aiming to improve patient care and reduce healthcare costs.
In its second quarter of 2025 financial report, Tactile Medical reported a revenue increase of 7.8% year-over-year, reaching $78.9 million, with a gross margin improvement to 75%. Despite the revenue growth, net income decreased to $3.2 million from $4.3 million in the same quarter of the previous year.
Key financial highlights include a significant 52% increase in sales of the airway clearance product line, driven by increased placements of AffloVest, and a modest 2% rise in the lymphedema product line. The company completed a $16.5 million share repurchase program and reported an adjusted EBITDA of $7.7 million. Strategic initiatives focused on expanding treatment options and improving patient access are underway, with expectations of more substantial benefits in 2026.
Looking ahead, Tactile Medical has updated its 2025 financial outlook, projecting total revenue between $310 million and $315 million, representing a 6% to 8% growth over 2024. The company anticipates an adjusted EBITDA range of $33 million to $35 million, reflecting its commitment to strategic investments and market expansion.